Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma

Eur J Gastroenterol Hepatol. 2013 Apr;25(4):514-5. doi: 10.1097/MEG.0b013e32835c04dd.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Carcinoma, Hepatocellular / therapy*
  • Drug Administration Schedule
  • Humans
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Niacinamide / administration & dosage
  • Niacinamide / analogs & derivatives*
  • Phenylurea Compounds / administration & dosage*
  • Radiotherapy, Adjuvant
  • Sorafenib
  • Yttrium Radioisotopes / therapeutic use

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Yttrium Radioisotopes
  • Niacinamide
  • Sorafenib